Company Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| Country | Belgium |
| Founded | 1999 |
| IPO Date | May 6, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,123 |
| CEO | Paulus Stoffels |
Contact Details
Address: Generaal De Wittelaan L11 A3 Mechelen, 2800 Belgium | |
| Phone | 32 1 534 29 00 |
| Website | glpg.com |
Stock Details
| Ticker Symbol | GLPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001421876 |
| CUSIP Number | 36315X101 |
| ISIN Number | US36315X1019 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paulus A. Stoffels M.D., Ph.D. | Chief Executive Officer, Chairman, Interim Head of Research & Development |
| Sofie Van Gijsel | Head of Investor Relations |
| Valeria Cnossen | Executive Vice President and General Counsel |
| Marieke Vermeersch | Head of Corporate Communication |
| Annelies Missotten | Executive Vice President and Chief Human Resources Officer |
| Ellen Van Der Aar | Head of Development |
| Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior Vice President and Head of Business Development |
| Alice Dietrich | Head of Medical Affairs |
| Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D. | Head of Small Molecules Discovery and Senior Vice President |
| Patrik Ringblom | Head of Strategy and US Lead |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 6-K | Report of foreign issuer |
| Oct 31, 2024 | 6-K | Report of foreign issuer |
| Oct 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 7, 2024 | 6-K | Report of foreign issuer |
| Sep 30, 2024 | 6-K | Report of foreign issuer |
| Sep 16, 2024 | 6-K | Report of foreign issuer |
| Sep 3, 2024 | 6-K | Report of foreign issuer |
| Aug 23, 2024 | 6-K | Report of foreign issuer |